Fibromyalgia News

Researchers found patients with fibromyalgia could be classified into one of several distinct subgroups based on three variables, which could in turn help guide individual patient management.

Patients with fibromyalgia had median ratings for cognitive function that were significantly worse than in patients with rheumatoid arthritis and reported more symptoms of impaired concentration, according to findings presented at the American College of Rheumatology Annual Meeting.

In a sample of Australian patients with chronic non-cancer pain, researchers found the use of marijuana for pain relief was very common, with patients reporting greater pain relief when using cannabis plus opioids compared with opioids alone.

More than half of newly diagnosed fibromyalgia patients were prescribed opioids and not a guideline medication, according to data presented at the American College of Rheumatology Annual Meeting.

A strong positive association was found between the presence of anti-thyroid antibodies and fibromyalgia and chronic widespread pain in patients with rheumatoid arthritis, according to study results presented at the American College of Rheumatology Annual Meeting.

Trends in controlling the abuse of opioid analgesic medications in the United States have made progress, according to data published in the New England Journal of Medicine.

The NIH has released panel recommendations for research into long-term use of opioids for chronic pain after researchers conducted an extensive review of literature. The findings were published today in The Annals of Internal Medicine.

Tonix Pharmaceuticals announced it has obtained written guidance from the FDA to begin a phase 3 trial of its sublingual form of cyclobenzaprine, TNX-102 SL, for the treatment of fibromyalgia.

Specific cytokines and chemokines were lower in fibromyalgia patients than in individuals with rheumatoid arthritis or systemic lupus erythematosus and in healthy control participants, according to new research.

A portion of patients fibromyalgia who took pregabalin in phase 2 and 3 clinical trials showed improved pain symptoms and sleep patterns as early as the first day of treatment, according to a post-hoc study of four similarly designed clinical trials.